There is no demonstrated benefit of Teva's Azilect (rasagiline) for slowing the rate of progression of Parkinson's disease, a US FDA drug reviewer said, insisting that the company's data were "not robust" enough to support such a claim.
While Dr Leonard Kapcala, a clinical reviewer in the FDA's Division of Neurology Products, said he was deferring his final...